EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences:
Goldman Sachs 44th Annual Healthcare Conference (Fireside Chat)
Fireside Chat Date and Time: Monday, June 12 at 4:00pm PT
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Dana Point, CA
Webcast: https://cc.webcasts.com/gold006/061223a_js/?entity=46_YF42184
SVB Securities Therapeutics Forum (1x1s)
Conference Dates: July 11-12, 2023
Location: New York, NY
The live webcast will also be available via https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
(973) 271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.47 |
Daily Change: | 0.0013 0.28 |
Daily Volume: | 2,399,377 |
Market Cap: | US$55.170M |
August 13, 2024 May 09, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB